Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CureVac (CVAC) Net Income towards Common Stockholders (2019 - 2025)

Historic Net Income towards Common Stockholders for CureVac (CVAC) over the last 7 years, with Q3 2025 value amounting to $399.7 million.

  • CureVac's Net Income towards Common Stockholders fell 970.36% to $399.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $277.5 million, marking a year-over-year increase of 3952.32%. This contributed to the annual value of $173.3 million for FY2024, which is 16191.36% up from last year.
  • CureVac's Net Income towards Common Stockholders amounted to $399.7 million in Q3 2025, which was down 970.36% from -$68.3 million recorded in Q2 2025.
  • In the past 5 years, CureVac's Net Income towards Common Stockholders ranged from a high of $442.7 million in Q3 2024 and a low of -$183.5 million during Q2 2021
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$68.3 million (2025), whereas its average is -$24.3 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first tumbled by 196018.44% in 2022, then surged by 93557.63% in 2024.
  • CureVac's Net Income towards Common Stockholders (Quarter) stood at -$6.4 million in 2021, then plummeted by 1960.18% to -$131.0 million in 2022, then grew by 28.77% to -$93.3 million in 2023, then fell by 16.52% to -$108.7 million in 2024, then surged by 467.64% to $399.7 million in 2025.
  • Its Net Income towards Common Stockholders stands at $399.7 million for Q3 2025, versus -$68.3 million for Q2 2025 and $54.8 million for Q1 2025.